159 related articles for article (PubMed ID: 38692813)
21. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Hanna NH; Robinson AG; Temin S; Baker S; Brahmer JR; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Moffitt PR; Phillips T; Riely GJ; Rosell R; Schiller JH; Schneider BJ; Singh N; Spigel DR; Tashbar J; Masters G
J Clin Oncol; 2021 Mar; 39(9):1040-1091. PubMed ID: 33591844
[TBL] [Abstract][Full Text] [Related]
22. Is tissue still the issue in detecting molecular alterations in lung cancer?
Liam CK; Mallawathantri S; Fong KM
Respirology; 2020 Sep; 25(9):933-943. PubMed ID: 32335992
[TBL] [Abstract][Full Text] [Related]
23. Predictive markers in lung cancer: a few hints for the practicing pathologist.
Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
[TBL] [Abstract][Full Text] [Related]
24. Molecular Pathology of Lung Cancer Cytology Specimens: A Concise Review.
Jain D; Roy-Chowdhuri S
Arch Pathol Lab Med; 2018 Sep; 142(9):1127-1133. PubMed ID: 29547001
[TBL] [Abstract][Full Text] [Related]
25. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.
Levy BP; Chioda MD; Herndon D; Longshore JW; Mohamed M; Ou SH; Reynolds C; Singh J; Wistuba II; Bunn PA; Hirsch FR
Oncologist; 2015 Oct; 20(10):1175-81. PubMed ID: 26330460
[TBL] [Abstract][Full Text] [Related]
26. Non-small cell lung cancer.
Ettinger DS; Akerley W; Bepler G; Blum MG; Chang A; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Ganti AK; Govindan R; Grannis FW; Jahan T; Jahanzeb M; Johnson DH; Kessinger A; Komaki R; Kong FM; Kris MG; Krug LM; Le QT; Lennes IT; Martins R; O'Malley J; Osarogiagbon RU; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Rohren E; Simon GR; Swanson SJ; Wood DE; Yang SC;
J Natl Compr Canc Netw; 2010 Jul; 8(7):740-801. PubMed ID: 20679538
[No Abstract] [Full Text] [Related]
27. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
28. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
Warth A
Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
[TBL] [Abstract][Full Text] [Related]
29. [Molecular diagnostics and imaging].
Fink C; Fisseler-Eckhoff A; Huss R; Nestle U
Onkologie; 2009; 32 Suppl 1():3-8. PubMed ID: 19521129
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
31. Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society.
Rajadurai P; Cheah PL; How SH; Liam CK; Annuar MAA; Omar N; Othman N; Marzuki NM; Pang YK; Bustamam RSA; Tho LM
Lung Cancer; 2019 Oct; 136():65-73. PubMed ID: 31446227
[TBL] [Abstract][Full Text] [Related]
32. [Liquid biopsy : A blood sample for early recognition and therapy control in lung cancer patients].
Hekmat K; Bruns C
Chirurg; 2017 Jul; 88(7):621. PubMed ID: 28616676
[No Abstract] [Full Text] [Related]
33. Current challenges and practical aspects of molecular pathology for non-small cell lung cancers.
Hofman P; Berezowska S; Kazdal D; Mograbi B; Ilié M; Stenzinger A; Hofman V
Virchows Arch; 2024 Feb; 484(2):233-246. PubMed ID: 37801103
[TBL] [Abstract][Full Text] [Related]
34. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
Gupta AR; Woodard GA; Jablons DM; Mann MJ; Kratz JR
Future Oncol; 2021 Dec; 17(34):4785-4795. PubMed ID: 34435876
[TBL] [Abstract][Full Text] [Related]
35. State of the Art of Pathologic and Molecular Testing.
Dacic S
Hematol Oncol Clin North Am; 2023 Jun; 37(3):463-473. PubMed ID: 36964109
[TBL] [Abstract][Full Text] [Related]
36. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
[TBL] [Abstract][Full Text] [Related]
37. Molecular testing in non-small cell lung cancer: A consensus recommendation.
Lai GGY; Cheng XM; Ang YL; Chua KLM; Samol J; Soo R; Tan DSW; Lim TKH; Lim DWT
Ann Acad Med Singap; 2023 Jul; 52(7):364-373. PubMed ID: 38904502
[TBL] [Abstract][Full Text] [Related]
38. Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
Canberk S; Engels M
Virchows Arch; 2021 Jan; 478(1):45-57. PubMed ID: 33389149
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.
Vigneswaran J; Tan YH; Murgu SD; Won BM; Patton KA; Villaflor VM; Hoffman PC; Hensing T; Hogarth DK; Malik R; MacMahon H; Mueller J; Simon CA; Vigneswaran WT; Wigfield CH; Ferguson MK; Husain AN; Vokes EE; Salgia R
Oncotarget; 2016 Apr; 7(14):18876-86. PubMed ID: 26934441
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review.
Zheng Y; Vioix H; Liu FX; Singh B; Sharma S; Sharda D
Future Oncol; 2022 Feb; 18(4):505-518. PubMed ID: 34865516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
